New findings from an international, large-scale clinical trial have found a significant reduction in the first occurrence of a heart attack, stroke, or death, and a reduction in progression of kidney disease in patients with type 2 diabetes (T2D) who received a weekly injection of efpeglenatide.
As a glucagon-like peptide-1 receptor agonist drug (GLP-1 RA), efpeglenatide is used to treat diabetes by reducing blood pressure, glucose levels, and weight. Earlier research results showed that GLP-1 RA drugs based on human GLP-1 reduce cardiovascular and kidney outcomes, and the AMPLITUDE-O trial (NCT03496298) assessed the impacts of a GLP-1 RA based on exendin-4 either with or without a sodium glucose co-transporter 2 inhibitor drug in patients with cardiovascular or kidney disease.
The clinical trial was conducted in 28 countries and included more than 4000 patients with T2D. Over 2 years, patients who received weekly injections of efpeglenatide vs a placebo had a 27% lower risk of a heart attack, stroke, or cardiovascular death, according to the American Diabetes Association (ADA).
Furthermore, investigators found a 32% lower risk of kidney disease progression and a 27% lower risk of heart attack, stroke, or death from any cause in the efpeglenatide arm.
The findings were presented at the virtual 81st Scientific Sessions of the ADA and simultaneously published in the New England Journal of Medicine.
[2:09 PM] Aislinn Antrim
Weekly injection of glucose-reducing drug offers safe and effective way to significantly reduce cardiorenal events for people with type 2 diabetes. News release. June 28, 2021. American Diabetes Association. Accessed September 9, 2021. https://www.diabetes.org/newsroom/press-releases/2021/weekly-injection-glucose-reducing-drug-offers-safe-effective-way-to-reduce-cardiorenal-events-for-t2d